Invasive Aspergillosis in India: Unique Challenges. Dr Rajeev Soman Consultant Physician PD Hinduja Hospital Mumbai

Similar documents
Invasive Pulmonary Aspergillosis in

Aspergillosis in the critically ill patient

ESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole

Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong

Top 5 papers in clinical mycology

2046: Fungal Infection Pre-Infusion Data

HAEMATOLOGY ANTIFUNGAL POLICY

TOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR

MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS

Aspergillus species. The clinical spectrum of pulmonary aspergillosis

Oliver A. Cornely. Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2. Centre for Clinical Research

TIMM 2013 Role of non-culture biomarkers for detection of fungal infections

Invasive Fungal Infections

Aspergillosis in Pediatric Patients

Challenges and controversies of Invasive fungal Infections

PAGL Inclusion Approved at January 2017 PGC

Is pre-emptive therapy a realistic approach?

Invasive Aspergillosis in Steroid-Treated Patients

ECMM Excellence Centers Quality Audit

Case Studies in Fungal Infections and Antifungal Therapy

PROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino

ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST

TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY

How Can We Tailor Antifungal Therapy?

Primary prophylaxis of invasive fungal infection in patients with haematological diseases

When is failure failure?

ESCMID Online Lecture Library. by author

Chronic pulmonary aspergillosis diagnosis and management in resource-limited setting

Outline NEW DIAGNOSTIC TOOLS WHY? WHICH TESTS? WHEN TO USE THEM? Documented IFI

High risk neutropenic patient (anticipated duration > 10 days) Send blood twice weekly for Beta -D Glucan Galactomanan Aspergillus PCR

Use of Antifungal Drugs in the Year 2006"

How Can We Prevent Invasive Fungal Disease?

Invasive Fungal Infections in Solid Organ Transplant Recipients

Update on Antifungal Stewardship

Pulmonary Aspergillosis

CLINICAL PATTERNS AMONG INVASIVE PULMONARY ASPERGILLOSIS PATIENTS WITH AND WITHOUT RECENT INTENSIVE IMMUNOSUPPRESSIVE THERAPY

Fungal Infections in Neutropenic Hematological Disorders

by author The Interaction Between Influenza and Aspergillus Carolina Garcia-Vidal Infectious Diseases Department Hospital Clínic Barcelona

Optimal Management of Invasive Aspergillosis in the Context of New Guidelines in High Risk Haematological Patients

WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?

Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?

Indre Vengalyte MD¹, Regina Pileckyte MD¹, Laimonas Griskevicius MD PhD 1, 2

Fungal Infections: Reporting. Marcie Tomblyn, MD, MS Associate Member, Moffitt Cancer Center

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

New Directions in Invasive Fungal Disease: Therapeutic Considerations

Treatment Guidelines for Invasive Aspergillosis

Controversies in management: prophylaxis or diagnostics

Management Strategies For Invasive Mycoses: An MD Anderson Perspective

ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS

Immunocompromised patients. Immunocompromised patients. Immunocompromised patients

Therapeutic management. complicated by invasive aspergillosis.

Introduction. Study of fungi called mycology.

Newer Combination Therapies

Pneumothorax: A Rare Presentation of. Pulmonary Mycetoma. Prem Parkash Gupta* Sanjay Fotedar* Dipti Agarwal** Kuldeep Saini* Sarita Magu***

Therapy of Hematologic Malignancies Period at high risk of IFI

Trust Guideline for the Use of Antifungals in Adults

Antifungals and current treatment guidelines in pediatrics and neonatology

No Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany

Tailored Antifungal Modification in Breakthrough Mold Infections. Russell E. Lewis University of Bologna

ESCMID Online Lecture Library. by author. CASE PRESENTATION ECCMID clinical grand round May Anat Stern, MD Rambam medical center Haifa, Israel

Common Fungi. Catherine Diamond MD MPH

Condition First line Alternative Comments Candidemia Nonneutropenic adults

Solid organ transplant patients

Antifungal Pharmacodynamics A Strategy to Optimize Efficacy

Invasive Fungal Infections in Critically Ill Patients. Dr Ravinder Kaur Director Professor&HOD Department of Microbiology,LHMC

ADVANCES AND CHALLENGES IN HEMATOLOGY. Invasive fungal disease management in febrile neutropenia

Approach to Fungal Infections

Monitorization, Separation and Quantification of Antifungals used for Invasive Aspergillosis Treatment by High Performance Thin Layer Chromatography

Use of Antifungals in the Year 2008

Antifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary

Dutch Working Party on Antibiotic Policy. SWAB Guidelines for the Management of Invasive Fungal Infections

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

The Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY

Surgical indications: Non-malignant pulmonary diseases. Punnarerk Thongcharoen

Respiratory Pathology. Kristine Krafts, M.D.

Micafungin, a new Echinocandin: Pediatric Development

Fungal Meningitis. Stefan Zimmerli Institute for infectious diseases University of Bern Friedbühlstrasse Bern

Antifungal Stewardship. Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul

Fungal Infection in the ICU: Current Controversies

EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS

MANAGEMENT OF PULMONARY MYCOSIS

Long Case Presentation

Clinical Management of Pulmonary Aspergillosis

Successful treatment of larynxtracheobronchial-pulmonary

Case Report Aspergillus Tracheobronchitis Causing Subtotal Tracheal Stenosis in a Liver Transplant Recipient

Treatment Guidelines for Invasive Aspergillosis

Fungal and Viral Infections

Fungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia

Fungal update. Liise-anne Pirofski, M.D. Albert Einstein College of Medicine

CD101: A Novel Echinocandin

Nasreen A. Syed, MD F.C. Blodi Eye Pathology Laboratory University of Iowa

posaconazole, or prayers

Diagnosis,Therapy and Prophylaxis of Fungal Diseases

Research priorities in medical mycology

Diagnostik invasiver Pilzinfektionen

Patient s s headache is our headache

Diagnostic Procedures for Pulmonary Infiltrates in the Compromised Host

Patient s s headache is our headache

amphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET

Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences

Transcription:

Invasive Aspergillosis in India: Unique Challenges Dr Rajeev Soman Consultant Physician PD Hinduja Hospital Mumbai

Aspergillus Challenges Capable of surviving & thriving in all the diverse environmental conditions in India Few other infectious agents produce such a variety of infectious & allergic syndromes Diagnosis requires invasive &/or hi-tech procedures Management requires pharmacological insights Prevention needs better identification of target populations

Diagnosis

EORTC/MSG criteria are only for use in clinical studies Failure to meet criteria does not rule out IA Conceptual framework tempts clinicians to extend it to other patient groups & also to make treatment decisions Proven IA Culture from a sterile site or Culture (to show Aspergillus) & histology (for invasion) from a non sterile site Difficult due to inaccessibility of the lesion & the physiologic condition of the patient Probable IPA Susceptible host Compatible clinico-radiologic syndrome Mycological test

Host factors Conventional neutropenia, immunocompromised states Non conventional COPD, ICU, malnutrition, liver disease, contaminated IV fluids, needles, ophthalmic surgery, IVDU Chakraborty A Med Mycol 2011;49(1):s35-47 Radiologic features Conventional dense nodule + halo, cavitation, cresent Nonspecific in non-neutropenic, overlap with TB Availability, cost of HRCT Mycological tests Sensitivity, specificity, availability, cost

SA 61 M DM LRKT recipient Tac MMF Prednisolone 3m later cough followed by fever, hemoptysis after 2 w Dense nodule, halo sign +ve BAL GM not available BAL Aspergillus PCR +ve Later on crescent like sign Treated with Voriconazole BAL TB MGIT culture turned +ve after 6 w Looked like Possible IPA Turned out to be TB

Does a firm alternative diagnosis (in a case of Possible IPA) lead to a rejected diagnosis of IPA?

NP 55 M LRKT recipient 7 y post transplant AZA PSN Fever, cough, Looked like miliary TB Turned out IPA & Nocardiosis * * *

Radiologic criteria from EORTC MSG Do not apply well to non neutropenic hosts CT in IPA in SOT recipients Bilateral nodules 74%, consolidation 46%, halo 29%, cavitation 29%, air crescent 3% Alexander BD M IDSA 2009 abstract#406 Have been commented on as being nonspecific, transient, observer dependent, not quantifiable, may worsen with treatment & derived from old studies before recent serologic tests & preventive therapy It is proposed that Probable IPA should be diagnosed without pre-specified radiologic criteria & greater weight should be given to mycological test results Nucci M CID 2010;51:1273-80

Mycological tests also have limitations Smear, culture has suboptimal sensitivity & specificity PPV varies from 17-72%, > 2 colonies has a high PPV PCR can be false +ve due to conidia colonizing the airways GM is released from growing hyphae, may provide a better evidence of actual infection Maertens J Aspergillosis: from Diagnosis to Prevention 2010 Needs to be performed on site, 3/w, cost constraints Neofytos D Editorial CID 2010;51:1281-3 False +ve Pip tazo, especially generic (but less likely with BAL GM), lab contamination, rare pathogens (Penicillium) False ve In non-neutropenic, with mould active prophylaxis, with Aspergillus tracheobronchitis

In neutropenic GM (index) BAL 100% (1) serum 90% (0.5) In non neutropenic GM BAL 94.7% serum 36.8% Maertens J CID 2010;50:1071-2 Due to lesser number of hyphae, smaller zone of infarction & more WBC in peripheral blood More likely +ve in patients with hemoptysis 52% vs 9% Park SY CID 2011;52:e149 OD >0.5 serum, >1 BAL Maertens J CID 2010;50:1071-2 Dynamic cut off 2 values > 0.5 or 1 of > 0.8 Maertens J Br J Haematol 2004;126:852-60 Different thresholds for different patients, samples & purposes such as screening or supporting the diagnosis Donnelly JP CID 2010;50:1070-1

Management

JM 55 F SLE on PSN AZA Presented elsewhere with dyspnea, no fever 4 blood cultures ve thought to be LSE or myxoma Severe headache thought to be tuberculomas started ATT

Presented to PDHNH 7 d later with sudden blindness History revealed headache was of sudden onset Diffusion weighted image showed infarct pattern Vitrectomy L eye string of pearls appearance & necrotic retina Suspected Aspergillus IE & emboli ATT was withdrawn Voriconazole started

At surgery, large vegetations, papillary muscle abscess, vegetations en plaque on the LV free wall, MVR done High dose Voriconazole maintained & Caspofungin added

Voriconazole drug of choice, clinical experience, cidal for Aspergillus, ocular & CNS penetration But was on Rifampin for 7 d which reduces Voriconazole levels by 95%, TDM not available AmB inferior results compared to Voriconazole but some uncertainty exists Echinocandins not clearly cidal, no ocular & CNS penetration Potential benefit of combination may be best realized in patients who are at the highest risk of adverse outcome Singh N Am J Transplantation 2009;9(4):s180-91 Surgery & immunomodulation are important

Dr AK 68 M Granulomatous invasive fungal rhino sinusitis (FRS) Long duration > 3m dense fibrotic reaction, scanty hyphae Chakraborty A Laryngoscope 2009;119:1809-18

Aspergillus keratitis Agriculture & outdoor workers exposed to dust, vegetable matter, injury due to tree branches, swish of a cow s tail Ocular procedures Scrapings for smear, culture Local & systemic antifungal therapy Surgery

The drugs for IA have important limitations related to GI absorption, interactions, penetration into various body sites & ADR They are available in this country ahead of adequate diagnostics & knowledge about their use There is a wide range in the cost & possibly also of biological activity of products available from various pharmaceutical companies This has led to inappropriate use, therapeutic failures & an enhanced need for TDM The prolonged duration of treatment poses further practical difficulties

Prevention

High risk groups who demonstrably benefit Profound, prolonged neutropenia, lung transplant & some liver transplant recipients Aerosolized L AmB, Voriconazole, Posaconazole Warm, dry weather allows greater dispersal of the hydrophobic spores Targeted prophylaxis at times of high spore circulation & in the presence of severe immunosuppression Viscoli C CID 2010;50:1598-600 Asepsis & infection control both in the hospital & in community medicine

Conclusion

More awareness about IA as a disease Unique epidemiology Better diagnostics Expertise in management Targeted preventive strategies Resource limitation